Compare FVCB & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FVCB | ZNTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.0M | 289.0M |
| IPO Year | 2018 | 2020 |
| Metric | FVCB | ZNTL |
|---|---|---|
| Price | $18.32 | $3.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $6.60 |
| AVG Volume (30 Days) | 65.0K | ★ 1.0M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 47.56 | 18.03 |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $1,781,000.00 | N/A |
| Revenue This Year | $13.83 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | $22.62 | ★ N/A |
| Revenue Growth | ★ 13.87 | N/A |
| 52 Week Low | $11.83 | $1.21 |
| 52 Week High | $19.11 | $6.95 |
| Indicator | FVCB | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 41.97 |
| Support Level | $18.12 | $3.46 |
| Resistance Level | $19.07 | $4.00 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 49.89 | 38.17 |
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.